Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 6,667 Shares of Stock

Key Points

• Anish Patel, COO of Enliven Therapeutics, sold 6,667 shares of the company's stock at an average price of $20.24, totaling $134,940.08, which decreased his ownership by 2.30%.
• Enliven Therapeutics shares have dropped by 2.5%, trading at $19.22, with a 52-week range between $13.30 and $30.03.
• Wall Street analysts have a consensus rating of "Buy" for Enliven Therapeutics, with an average price target of $41.20, reflecting positive expectations for the company's growth.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) COO Anish Patel sold 6,667 shares of the company's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $20.24, for a total value of $134,940.08. Following the completion of the transaction, the chief operating officer owned 283,308 shares of the company's stock, valued at $5,734,153.92. The trade was a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Anish Patel also recently made the following trade(s):

• On Thursday, August 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.24, for a total value of $121,606.08.
• On Monday, July 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $19.79, for a total value of $131,939.93.

Enliven Therapeutics Stock Down 2.5%

Shares of ELVN traded down $0.50 during trading hours on Wednesday, hitting $19.22. The company had a trading volume of 369,670 shares, compared to its average volume of 419,351. The stock's 50 day moving average price is $20.37 and its 200 day moving average price is $19.72. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, beating analysts' consensus estimates of ($0.53) by $0.04. On average, equities analysts expect that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its stake in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after acquiring an additional 1,114 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Enliven Therapeutics by 3,058.1% during the first quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock valued at $53,000 after buying an additional 2,630 shares during the last quarter. Quantbot Technologies LP bought a new position in Enliven Therapeutics in the 1st quarter valued at approximately $60,000. BNP Paribas Financial Markets boosted its stake in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after purchasing an additional 930 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Enliven Therapeutics by 194.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company's stock worth $106,000 after purchasing an additional 3,490 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ELVN. The Goldman Sachs Group began coverage on shares of Enliven Therapeutics in a report on Monday, June 16th. They set a "buy" rating and a $37.00 target price for the company. Robert W. Baird boosted their target price on Enliven Therapeutics from $40.00 to $52.00 and gave the company an "outperform" rating in a research note on Monday, June 16th. Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a report on Friday, May 16th. Finally, HC Wainwright lifted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the company a "buy" rating in a report on Wednesday, July 2nd. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $41.20.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.